Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 527.36 -7.81 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $535.17 | 52 Week High | $134.71 | |||
| Open | $531.66 | 52 Week Low | $73.31 | |||
| Day High | $533.08 | P/E | N/A | |||
| Day Low | $522.91 | EPS | $-1.98 | |||
| Volume | 297,193 | |||||
